Sponsors / CLDX
CLDX

Celldex Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
9Trials in this database
23Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaNCT05368285Celldex TherapeuticsPhase 2Completed2023-09-28Actual
A Study of CDX-0159 in Patients With Chronic Inducible UrticariaNCT05405660Celldex TherapeuticsPhase 2Completed2024-06-12Actual
A Study of CDX-0159 in Patients With Eosinophilic EsophagitisNCT05774184Celldex TherapeuticsPhase 2Completed2025-06-04Actual
A Study of Barzolvolimab in Patients With Prurigo NodularisNCT06366750Celldex TherapeuticsPhase 2Active not recruiting2026-03-17Actual
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023Celldex TherapeuticsPhase 3Active not recruiting2026-10Estimated
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202Celldex TherapeuticsPhase 3Active not recruiting2026-10Estimated
A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552Celldex TherapeuticsPhase 2Active not recruiting2026-05-06Actual
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT07256392Celldex TherapeuticsPhase 3Enrolling by invitation2028-09Estimated
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)NCT07266402Celldex TherapeuticsPhase 3Recruiting2028-06Estimated

Latest recorded trial changes

A Study of Barzolvolimab in Patients With Atopic Dermatitis

NCT06727552 · Celldex Therapeutics

· 3 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

120 participants (planned)

+ After

131 participants (actual)

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source
A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750 · Celldex Therapeutics

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

120 participants (planned)

+ After

140 participants (actual)

Primary completion date changed

− Before

Jan 2026

+ After

Jun 2026

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source